Date: 2014-06-18
Type of information: Grant
Company: Ziarco (UK)
Investors: Technology Strategy Board (UK)
Amount: £1.7m (€2.1 million)
Funding type: grant
Planned used: The grant will be used by Ziarco to further develop ZPL-389, a novel, oral antagonist of histamine H4 receptor which is in clinical development to treat a number of dermatological, and potentially other inflammatory diseases. Specifically, the funding will be used to support a Phase 2a clinical study to further evaluate the safety and efficacy of ZPL-389 in patients with Atopic Dermatitis. ZPL-389 has already been studied in over 60 subjects in two different countries. Ziarco believes that ZPL-389 is one of only two clinical-stage oral H4 antagonists in active development. Previously, ZPL-389 has completed a 14 day multi-dose study as well as earlier Phase I studies incorporating a dose-setting biomarker. With the recent completion of additional subchronic non-clinical toxicology work, ZPL-389 is ready for patient studies which are the subject of the TSB grant.
Others: * On June 18, 2014, Ziarco Pharma, a biopharmaceutical company focusing on steroid-unresponsive inflammation and allergic diseases, announced this prestigious award of grant funding from the Technology Strategy Board (TSB).
Therapeutic area: Dermatological diseases - Immunological diseases - Inflammatory diseases
